Table 1.

Published hyperthermia (HT) with immunotherapy (IT) studies in human patients.

Author	HT method	IT Agent	Population	Outcome	Complications
Paiva et al.	LITT	IL-2 infusion in the week after LITT	Two adult patients with renal cell carcinoma metastases to the head and neck	Patient 1 passed 2 years later from metastases to the lungs Patient 2 passed 20 months after treatment	None
Qiao et al.	RFA	10 received ACT, 11 received ACT and pembrolizumab, 12 received ACT and CT	33 patients with ovarian, pancreatic, gastric, colorectal, cervical, or endometrial cancer	30% objective response rate, 66.7% disease control rate with 9.1% complete responses and 21.2% partial responses	Blistering (3/33), subcutaneous fat induration (4/33), local hear-related pain (3/33), vomiting (1/33), and sinus tachycardia (1/33)

ACT: adoptive T cell therapy; CT: chemotherapy; LITT: laser interstitial thermal therapy; RFA: radiofrequency ablation.